BeOne Medicines
ONC
#629
Rank
HK$312.83 B
Marketcap
HK$2,750
Share price
-1.15%
Change (1 day)
8.09%
Change (1 year)
BeOne Medicines formerly known as BeiGene, is a multinational pharmaceutical company engaged in the R&D, commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

EPS for BeOne Medicines (ONC)

EPS in 2026 (TTM): HK$46.78

According to BeOne Medicines's latest financial reports the company's current EPS (TTM) is HK$46.93. In 2025 the company made an earnings per share (EPS) of HK$21.42 an increase over its 2024 EPS that were of -HK$48.97.

EPS history for BeOne Medicines from 2015 to 2026

Annual EPS

Year EPS Change
2026 (TTM)HK$46.78118.35%
2025HK$21.42-143.75%
2024-HK$48.97
2022-HK$153.0328.21%
2021-HK$119.36-19.96%
2020-HK$149.1320.81%
2019-HK$123.4431.52%
2018-HK$93.86417.57%
2017-HK$18.13-37.16%
2016-HK$28.86158.95%
2015-HK$11.14

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
OPKO Health
OPK
-HK$0.71-101.51%๐Ÿ‡บ๐Ÿ‡ธ USA
Onconova Therapeutics
ONTX
-HK$7.46-115.89%๐Ÿ‡บ๐Ÿ‡ธ USA